Cramer Says This ‘Inexpensive’ Stock Is ‘Doing Some Great Things With Aerospace’
Jim Cramer said WK Kellogg Co (NYSE: KLG) doesn’t have a "lot of growth, and it doesn’t have a lot of yield." He prefers Kellanova (NYSE: K)
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole remaining clinical-stage player with a robust supply chain.
Investor Sentiment Improves; Dow Jumps Over 150 Points
The CNN Money Fear and Greed index showed an increase in overall market sentiment, while the index remained in the "Extreme Greed" zone on Tuesday.
Nasdaq Surges 75 Points; Inspira Technologies Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 150 points on Tuesday.
The Dow traded up 0.50% to 37,574.66 while the NASDAQ rose 0.50% to 15,068.50. The S&P 500 also rose, gaining, 0.45% to 4,776.17.
Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of RayzeBio, Inc. (NASDAQ: RYZB) rose sharply during Tuesday’s session after the company announced that it will be acquired by Bristol Myers Squibb for $62.50 per share in cash in a deal worth $4.1 billion.
RayzeBio shares gained 100% to $61.38 on Tuesday.
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers RayzeBio (NASDAQ:RYZB) stock moved upwards by 100.8% to $61.4 during Tuesday’s regular session. The market value of…
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
Bristol-Myers Squibb (NYSE:BMY) has announced a merger with RayzeBio (NASDAQ:RYZB) that is expected to be completed 2024-H1. Under…
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of <
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers RayzeBio (NASDAQ:RYZB) stock rose 98.2% to $60.6 during Tuesday’s pre-market session. The company’s market cap stands at…